Compare
UroGen Pharma Ltd. vs Zevra Therapeutics, Inc. vs Gyre Therapeutics, Inc. vs Xencor Inc
| Latest fiscal year | UroGen Pharma Ltd. URGN | Zevra Therapeutics, Inc. ZVRA | Gyre Therapeutics, Inc. GYRE | Xencor Inc XNCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $109.79M | $106.47M | $116.59M | $125.58M |
| Revenue growth (YoY) | +21.4% | +350.9% | +10.2% | +13.7% |
| Gross margin | 88.7% | n/a | n/a | n/a |
| Operating margin | -113.7% | -59.1% | 9.9% | -141.4% |
| Net margin | -139.8% | 78.2% | 8.5% | -73.2% |
| Net income | -$153.49M | $83.23M | $9.88M | -$91.92M |
| EPS (Diluted) | n/a | $1.35 | $0.02 | -$1.24 |
| Operating cash flow | -$162.44M | -$1.60M | $1.01M | -$135.12M |
| Free cash flow | -$162.73M | -$2.43M | -$180.0K | -$138.27M |
| Cash & equivalents | $110.75M | $62.41M | $37.07M | $54.07M |
| Total assets | $200.46M | $284.73M | $166.13M | $875.50M |
| Total liabilities | $305.93M | $130.07M | $23.85M | $239.91M |
| Shareholders' equity | -$105.47M | $154.66M | $106.03M | $635.59M |
| Return on year-end equity | n/a | 53.8% | 9.3% | -14.5% |
| Shares outstanding | 48.35M | 56.85M | 91.31M | 71.87M |
Revenue, most recent five fiscal years
| Fiscal year | UroGen Pharma Ltd. | Zevra Therapeutics, Inc. | Gyre Therapeutics, Inc. | Xencor Inc |
|---|---|---|---|---|
| Latest | $109.79M Ended 2025-12-31 | $106.47M Ended 2025-12-31 | $116.59M Ended 2025-12-31 | $125.58M Ended 2025-12-31 |
| 1 year earlier | $90.40M Ended 2024-12-31 | $23.61M Ended 2024-12-31 | $105.76M Ended 2024-12-31 | $110.49M Ended 2024-12-31 |
| 2 years earlier | $82.71M Ended 2023-12-31 | $27.46M Ended 2023-12-31 | $113.45M Ended 2023-12-31 | $174.62M Ended 2023-12-31 |
| 3 years earlier | $64.36M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | $102.29M Ended 2022-12-31 | $164.58M Ended 2022-12-31 |
| 4 years earlier | $48.04M Ended 2021-12-31 | $28.65M Ended 2021-12-31 | $7.34M Ended 2021-12-31 | $275.11M Ended 2021-12-31 |